Want to see HRGN full AI Analyst Report?
Harvard Apparatus Regenerative Technology (HRGN) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cellspan™ Esophageal Implant-Adult (Cei) | Esophageal Diseases | Phase I | Recruiting | Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement | May 05, 2023 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cellspan™ Esophageal Implant-Adult (Cei) | Phase I | Esophageal Diseases | Recruiting | Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement | May 05, 2023 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Harvard Apparatus Regenerative Technology Inc (HRGN) have in its pipeline
Harvard Apparatus Regenerative Technology HRGN is currently developing the following drugs: Cellspan™ Esophageal Implant-Adult (Cei). These drug candidates are in various stages of clinical development as the company works toward FDA approval.
